| Abstrakt: |
Treatment with the bisphosphonate risedronic acid appears to protect against anastrozole-induced bone loss in women without breast cancer, according to results of the bone substudy of the International Breast Cancer Prevention Study (IBIS-Ill). This study, results of which were presented at the 30th Annual San Antonio Breast Cancer Symposium (SABCS) [San Antonio, Texas, US; December 2007], revealed that bone loss associated with anastrozole "may be manageable with DXA monitoring and bisphosphonates at doses licensed for osteoporosis," said lead investigator and study presenter Dr Shalini Singh (Wolfson Institute of Preventive Medicine, University of London, UK). [ABSTRACT FROM AUTHOR] |
